Esophageal achalasia is a primary motility disorder characterized by impaired lower esophageal sphinc ter relaxation and absence of esophageal peristalsis leading to impa ired bolus transit, manifested with symptoms such as dysphagia, regurgitation, retrosternal pain, and weight loss. Th e standard diagnostic tool is esophageal manometry which demonstrates incomplete relaxation of the lower esophageal sphincter and impaired esophageal peristalsis. Recently, a new advanced technique, high-resolution manometry (HRM) with the addition of pressure topography plotting, using multip le sensors to capture the manometric data as a spatial continuum, allows a detailed pressure recording of the esophageal motility. Th is technique, currently th e gold standard for the diagnosis of achalasia, has led to a subclassifi cation of three manometric types that seem to have diff erent responsiveness to treatment. Because its pathogenesis is as yet unknown, achalasia treatment options are not curativ e. Type II achalasia patients respond better to treatment compared to those with types I and III. Low-risk patients with type I or II achalasia have good outcome with both graded pneumatic dilatations and laparoscopic Heller myotomy, while type III achalasia patients respond better to laparoscopic Heller myotomy. Although, type III achalasia patients responds less in comparison to types I and II to laparoscopic Heller myotomy. Peroral endoscopic myotomy is a promising new technique but long-term follow-up studies for its safety and effi cacy must be performed. Th is article reviews the current therapeutic options, highlighting the impact of HRM to predict the outcome and the new insights for the treatment of achalasia.
Introduction
Achalasia is a rare primary esophageal motor disorder characterized by the absence of peristalsis and a defective relaxation of the lower esophageal sphincter ( LES) resulting in impaired bolus transport and food stasis in the esophagus [1] . Achalasia occurs equally in men and women with an incidence of 1 in 100,000 individuals and a prevalence of 10 in 100,000. Th e peak incidence occurs between 30 and 60 years of age [2, 3] . Th e most frequent symptoms of achalas ia are dysphagia for both solids and liquids, regurgitation of saliva and undigested food, resp iratory complications (nocturnal cough and aspiration), chest pain, heartburn, and weight loss [4] . Heartburn can mimic gastroesophageal refl ux disease (GERD). Dysphagia and regurgitation usually respond to t reatment, but chest pain is much more diffi cult to treat [5] . Th e Eckardt symptom score is the grading system most frequen tly used for the evaluation of symptoms, stages and effi cacy of achalasia treatment. A symptom score of 0-1 corresponds to clini cal stage 0, a score of 2-3 to stage I, a score of 4-6 to stage II, and a score >6 to stage III. Stages 0 and I indicate remission of the disease. On the other hand, stages II a nd III represent failure of treatment (Table 1) [6, 7] . Th e pathogenesis of achalasia is not well understood but it is believed to be due to an infl ammatory neurodegenerative process with possible viral involvement. Measl es and herpes viruses have been suggested as causal candidates. However, molecular techniques have failed to confi rm these claims and the causative agent remains undiscovered [8] . It has been hypothesized that an autoimmune pr ocess triggered by a still unidentifi ed cause results, in a genetically predisposed subject, in chronic infl ammatory process leading to neuronal damage [9] . Th is chronic infl ammation within the esophagus leads to the loss of postganglionic inhibitory neurons in the myenteric plexus and a consequent reduction in the inhibitory transmitters, nitric oxide and vasoactive intestinal pept ide. The excitatory neurons remain unaffected; this causes an imbalance between excitatory and inhibitory neurons that prevents LES relaxation [10, 11] . The first diag nostic step is to exclude a benign or malignant obstruction using endoscopy or radiology. In early stages, both tests may be completely normal. In advanced cases, the esophagus will be dilated with retained food and saliva; endosc opically, the esophagogastric junction will have a rosette appearance sometimes with increased resistance to scope passage into the stomach. Barium studies show a "bird beak" appearance from t he non-relaxing LES, varying degrees of esophageal dilation up to sigmoid esophagus, aperistalsis and sometimes an air-fluid level and absence of the gastric air bubble. To assess esophageal emptying, a timed barium swallo w can be done, in which the height of the barium column at 5 min after ingesting 8 oz (236 mL) of barium is a good measure of esophageal emptying [5] . Manometry is still the gold standard di agnostic test for achalasia [12] . On conventional manometry, the main features of achalasia are: absence of peristalsis, sometimes with increased intraesophageal pressure, and incomplete relaxation of the LES on deglutition (residual pressure >10 mmHg ) [13] . An increase in the resting tone of the LES is often observed [4] . However, the accuracy of these traditional studies has been challenged by the recent emergence of advanced techniques for the diagnosis of esophageal achalasia such as highresolution manometry (HRM) and the addition of pressure topography plotting [12] . The use of multiple high-sensitivity sensors to capture manometric data as a spatial continuum allows a detailed pressure recording from the pharynx to the stom ach and is regarded as the gold standard for diagnosis of achalasia [4, 14] . Diagnostic algorithms for defining conventional manometric diagnoses of achalasia are improved with HRM, primarily due to the objectivity and accuracy with which it identifies impaired esophagogastric junction relaxation and the metric of peristaltic contraction [14] . The use of HRM has led to the subclassification of achalasia (Chicago classification) into three clinically relevant groups based on the contractility pattern in the esophageal body ( Table 2 , Fig. 1 ):
Type I (classic achalasia) no signifi cant pressurization within the esophageal body and impaired LES relaxation Type II (achalasia with compression or compartmentalization in the distal esophagus >30 mm Hg) rapid panesophageal pressurization with water swallows Type III (spastic ac halasia) rapidly propagated pressurization attributable to an abnormal lumen obliterating contraction Additionally, HRM introduced a new parameter for quantifi cation of the LES relaxation: integrated relaxation pressure, which calculates the mean post-swallow LES pressure of a 4 sec period during w hich the LES pressure was the lowest, skipping periods of crural contractions if necessary. Th e upper normal limit for the integrated relaxation pressure is 10 mmHg for type I achalasia, 15 mmHg for type II and 17 mmHg for type III achalasia, which diff erentiates best the impaired relaxation in achalasia from non-achalasia individuals and from patients with diff use esophageal spasm [15] .
Treatment of achalasia
Because of the unknown pathogenesis of achalasia, a healing treatment is not available nowadays. Palliative treatment options are aimed to reduce the gradient across the LES, relieving the primary symptoms of dysphagia and regurgitation, improving esophageal emptying, and preventing the development of megaesophagus [16] . Treatment modal ities include: pharmacological therapy, endoscopic injection of botulinum toxin (Botox), pneumatic dilatation (PD), laparoscopic Heller myotomy (LHM), and peroral endoscopic esophageal myotomy (POEM) [3, 4] . No intervention signifi cantly aff ects esophageal peristalsis and despite therapeutic interventions LES hypertonicity returns overtime, requiring repeated procedures [2] .
Pharmacological therapy
Pharmacological management usually has a minor role in the treatment of esophageal achalasia because is the least eff ective option [17] . Th e two most com monly used pharmacological agents are nitrates and calcium channel blockers. Nitrates inhibit normal LES contraction by increasing nitric oxide concentration in smooth muscle cells, which, in turn, i ncreases cyclic adenosine monophosphate levels promoting muscle relaxation. Wen et al in a recent review identifi ed only two randomized studies assessing the success of nitrates in the treatment of achalasia. Th ey concluded that no solid recommendations could be given [18] . Calcium antagonists block calcium entry and hence e sophageal muscle contraction. Nifedipine, in sublingual doses of 10-20 mg, 15-30 min before meals is the most used oral drug for achalasia. It inhibits LES contraction and decreases his resting pressure up to 60% [17] . Th e clinical response is of short duration because drug tolerance develops rapidly; symptoms improvement is incomplete and side eff ects such as headache, hypotension and leg edema are common limiting factors in their use. Th us, these drugs are commonly reserved for patients who cannot or refuse to undergo other more invasive therapies and for those in whom Botox has failed [2] .
Endoscopic injection of Botox
Botox is a biological neurotoxin derived from Clostridium botulinum that causes paralysis of both voluntary and involuntary muscles by blocking the release of acetylcholine from the nerve terminal endings. Its action persists for 3 to 4 months on average [19] . Th ere are fi ve commercial formulations of Botox with varying potencies. Th e majority of the studies report the use of Botox (Allergan Inc., Irvine, California, USA) and studies comparing Botox and Dysport (Ipsen Pharma, Boulogne-Billancourt, France) described similar clinical outcomes as far as the dose is adjusted according to the variable potency of the diff erent formulations [20] . Botox A is injected at a dose of 80-100 U in four quadrants just above the Z line into the LES through a sclerotherapy needle during an upper gastrointestinal endoscopy. Botox inje ction is safe with only minor complications such as transient pain (25% of the patients) and refl ux symptoms (less than 5%). Serious side eff ects such as mediastinitis and allergic reactions related to egg protein are rare. Doses higher than 100 U have not been proven to be more eff ective [21, 22] . More than 75% of cases have an initial clinical r esponse but the success rate fades rapidly to less than 60% at one year. About 50% of patients relapse and require repeat treatments at 6-24 months aft er the fi rst treatment [21] [22] [23] . Prolonged responses have been reported in older patients with a vigorous manometric pattern [22] , however, this may be more akin to the type II pattern associated with panesophageal pressurization by HRM [24] . Five randomized trials comparing Botox injection to PD and one to LHM have shown that there is initially a comparable relief from dysphagia but a rapid deterioration in the group of the patients treated with Botox injection aft er 6-12 months [23, [25] [26] [27] [28] [29] . Additionally, serial Botox injections are more expensive than PD [16] . Th ere is some evidence that multiple Botox injections into the LES could aff ect the results of a subsequent surgical myotomy [25] . Considering these limitations, the use of Botox injections should be restricted to elderly patients and those with comorbidities who are not candidates for PD and LHM.
PD
PD of the LES is considered the most eff ective nonsurgical treatment for achalasia [30] . PD uses air pressure to dilate intraluminally and disrupt the circu lar muscle fi bers of the LES. Th e most commonly used dilator is the Micro-invasive Rigifl ex Balloon system (Boston Scientifi c Corp, Boston, Massachusetts, USA). Th ese balloons are available in three diameters (30, 35 and 40 mm) mounted on a fl exible catheter placed over an endoscopic guidewire. Under sedation and under fl uoroscopic guidance the balloon is positioned across the LES and gradually infl ated until the waist is planed, using 7-15 psi of air, held for 15-60 sec [16] . Th e actual protocol varies across centers [13] . Th e most used protocol is a graded dilatation starting with a 30 mm balloon and subsequent dilations spaced over variable time intervals (2-4 weeks) on the basis of clinical sym ptom relief (Eckardt symptom score) or repeat LES pressure measurements or esophageal emptying improvement [31] [32] [33] [34] [35] . Aft er the procedure the patients should undergo a gastrografi n radiograph followed by bari um esophagogram to exclude esophageal perforation [36] . However, it is our opinion that radiographic testing with gastrografi n or barium should not be performed if the patient has pain and a perforation is suspected. In fact, in this case, gastrografi n may increase the diameter of a small esophageal perforation and the resulting mediastinal contamination may make nonsurgical management impossible. In such cases, a computed tomography to identify free air might represent a bette r choice. PD may be performed as an outpatient procedure. Patients without suspicion of esophageal perforation may undergo radiographic testing aft er an observation of 4-6 h and could b e discharged if negative. Patients can return to normal activities the next day. However, patients should be instructed to pursue immediate care if they reveal se vere chest pain with or without fever as delayed perforation has been reported possibly related to postprocedure vomiting [2] . Many studies suggest that by using graded dilator approach, good to excell ent relief of symptoms is possible in 50-93% of the treated patients [2, [37] [38] [39] . Richter et al, in a review of nearly 1200 patients from 24 studies with an average follow up of 37 months, reported that PD with Rigifl ex balloon resulted in good to excellent relief of the symptoms in 74%, 86% and 90 % of patients treated with 30, 35 and 40 mm balloon, respectively. One third of the patients will have a relapse of their symptoms over a 5-year period, however a long-term remission can be achieved in most of the patients by "on demand" repeat PD based on symptom recurrence [40, 41] . Predictors of the best clinical outcomes aft er PD include: age older than 40 years, women, LES pressure aft er dilatation <10 mmHg and type II pattern by HRM [5, 6, 12, 31, 34, 42, 43] . Th irty three percent of patients experience procedure-related complications, but most of them are minor such as chest pain, bleeding, aspiration pneumonia, fever, esophageal hematoma, and mucosal tear without perforation [44] . Th e most serious complication associated with PD is esophageal perforation with an overall median rate in experienced hands of 1.9% (range 0-16) [31, 34] . Conservative therapy with antibiotic and parenteral nutrition may be eff ective in small perforations and painful deep tears, but surgical repair through thoracotomy is the best approach for large perforations with extensive mediastinal contamination [45] . Most of the perforations occur during the fi rst dilatation. Th e diffi culty of keeping the balloon in an appropriate position seems to be a potential risk factor [46] . Boeckxstaens et al in their achalasia trial reported more perforations, primarily in older patients, when the fi rst PD was performed with a 35 mm versus a 30 mm balloon [6] . GERD may occur aft er PD in a range of 15-35% of the patients and PPI therapy can improve their refl ux-related symptoms [40] . PD is the most cost-eff ective treatment for achalasia over a 5-10-year follow-up period [47, 48] .
LHM
Th e surgical procedure most widely used to treat achalasia is Heller myotomy, fi rst described in 1913 by Ernst Heller and used ever since with a few technical modifi cations [49] . Th e two changes that modifi ed the initial Heller procedure are cutting of the anterior side of the cardia muscle fi bers only and the association of a fundoplication to reduce the development of GERD [50, 51] , the most frequent complication aft er myotomy without fundoplication. Th e technique evolved initially with a laparotomy approach followed by a successful thoracoscopic approach. However, in 1991 Shimi et al described a minimally invasive technique for LHM that has become the preferred method because of lower morbidity and faster recovery [52, 53] . A recent meta-analysis by Campos et al demonstrated that a LHM (3086 patients) improved the symptoms signifi cantly more than the thoracoscopic approach (211 patients) (89.3% vs. 77.6, P=0.048) and reduced the incidence of postoperative GERD (14.9% vs. 28.3%, P=0.03). Campos et al also showed that the addition of an antirefl ux procedure such as fundoplication on LHM, reduced signifi cantly further the gastroesophageal refl ux symptoms (31.5% vs. 8.8%) with a similar therapeutic success [38] . Richards et al demonstrated the benefi t of adding a fundoplication on LHM in a double-blind randomized trial comparing myotomy with or without fundoplication [54] . Th ere is less certainty on the type of fundoplication applied to obtain a better outcome. Postoperative dysphagia is signifi cantly higher aft er a Nissen fundoplication than aft er partial anterior approach [55] . A recent multicenter randomized controlled trial comparing anterior Dor and posterior Toupet approach suggested that both provide similar control of refl ux aft er LHM [56, 57] . Overall, LHM with partial fundoplication is a very safe operation with a mortality rate of 0.1% [4] . Clinical success rates are very high, with a mean success rate of 89% (range 76-100%) at a follow up of 35 months [38] . However, the success rates aft er 5 years drop to 65-85%, probably as a result of disease progression [58, 59] . Younger men (<40 years), a LES pressure greater than 30 mmHg and a straight esophagus (without distal tortuosities) are positive prognostic factors for a successful LHM [60, 61] . As for PD, the manometric subtype also aff ects the success rates of LHM. Patients with type II HRM achalasia pattern have the best outcome [62] . Th ere is no diff erence in clinical success rates between PD and LHM for patients with types I and type II achalasia, but the type III pattern responds better to surgery than to PD, probably because of the more extensive proximal disruption of the esophageal muscle [42, 62] . It is important to be very cautious in patients treated previously with intrasphincteric injection of Botox, as fi brosis can be present at the level of gastroesophageal juction. In these cases, myotomy has an increased risk of mucosal perforation. Portale et al reported that patients who previously underwent Botox injection and PD had less successful outcome in LHM than the patients who had not had such treatments [54, 63, 64] .
Th e most common complication of LHM is perforation of the esophageal or gastric mucosa (average 6.3%) during the myotomy, usually repaired without clinical consequences [65] . Recurrence of dysphagia usually develops aft er LHM within 12-18 months. Most oft en the cause is an incomplete myotomy on the gastric side where the dissection is more complicated, late scarring of the myotomy and an obstructive antirefl ux wrap [13, 66] . Recurrences aft er LHM can be treated with success with PD and in case of failure of this with a new LHM [66] .
PD versus LHM
At present, PD and LHM are the most eff ective treatment options for achalasia. Th e decision of which approach to undertake is diffi cult because of the lack of a large randomized controlled trial. Campos et al in their review of case series reported an improvement rate of 68% in 1065 patients treated with PD versus an 89% improvement rate of LHM in 3086 patients [38] . In 2006, a cross-sectional study by Vela et al showed similar success rates for PD and LHM. 106 patients underwent PD and 73 patients were treated with LHM. Success rates, defi ned as regurgitation or dysphagia less than three times per week or no alternative treatments, were 96% for PD group vs. 98% for LHM group at 6 months of follow up. Th e success rates were decreased to 44% vs. 57% at 6 years [31] . In 2007 Kostic et al performed a randomized controlled trial that compared PD with Rigifl ex balloon to LHM with Toupet fundoplication [67] . Th e results showed a superiority of the surgery procedure, but the limitations were that only 51 patients were studied with a limited follow up of only 1 year [67] . Finally, in 2011 Boeckstaens et al reported the results of the European Achalasia Trial, a prospective randomized clinical trial comparing PD and LHM with Dor fundoplication. 201 patients were randomized to receive either PD with Rigifl ex balloon (30 and 35 mm with up to three repeat dilatations) or LHM. Th erapeutic success was defi ned as a reduction in the Eckardt symptom score below 4. Aft er two years of follow up, comparable therapeutic success rates of 86% and 90% were observed for PD and LHM respectively. Both barium emptying and LES pressure improved to similar extents in both groups. Redilatation was performed in 23 of 95 patients (25%). Based on these data, the authors concluded that LHM does not achieve superior rates of therapeutic success compared with PD as primary treatment for achalasia, at least aft er a mean follow up of 43 months, and, therefore, either one can be recommended as an initial therapy.
POEM
Although the current treatments for achalasia are eff ective, PD is associated with the necessity of retreatment (25%) and surgical myotomy still requires laparoscopy and dissection of the gastroesophageal junction. Th us, there has been interest in developing a new technique that incorporates an endoscopic approach with principles of natural orifi ce transluminal endoscopic surgery to perform a myotomy. Th is technique is termed POEM [68] . A 2 cm longitudinal mucosal incision is made on the mucosal surface to create a mucosal entry to the submucosal space. Th en a submucosal tunnel is made to reach the LES and to dissect the circular muscle fi bers over a 7 cm esophageal and 2 cm gastric length. Inoue et al studied 17 patients and reported a success rate of 100% and a signifi cant reduction of LES pressure [2, 6] . A series of other studies confi rmed the high success rate (85-100%) even aft er several previous PD, even though the follow up was only 6 months [39, [69] [70] [71] [72] . Moreover, because no antirefl ux procedure is included in this technique, the risk to develop GERD is up to 46% [39] . Longer follow up and randomized prospective controlled trials with standard LHM and/or PD are needed before accepting POEM as a new treatment option for achalasia.
Other therapies

Self-expanding metallic stents
A few studies have reported the utility of self-expanding metallic stents for the treatment of achalasia. Th e stents gradually expand at body temperature over 24 h, resulting in more predictable tearing of the cardia muscle, less tissue scarring, and a lower rate of stenosis aft er the removal of the stent [73, 74] . Recently, a prospective randomized study evaluating the long-term effi cacy of a partially covered removable metallic stent versus PD was reported from a group in China. Li et al reported a clinical success rate of 83% for the 30 mm stent at 10 years, whereas the success rate for 20 mm stent and PD was 0%. However, the dilatation protocol was less aggressive than the standard technique used in Europe with a maximal diameter of 32 mm [74] . In another, singlecenter long-term prospective study, Zhao et al reported, using a 30 mm metallic stent, a clinical success rate of >80%. No perforation or mortality was reported, but stent migration occurred in 5% of patients, GERD in 20%, and chest pain in 38.7% [73] . Although these results appear promising, this technique needs to be evaluated more and tested in comparison with the therapeutic protocols of PD and LHM used in Europe and the US.
Endoscopic sclerotherapy
Recently, diff erent studies of Spanish and Iranian investigators reported the use of ethanolamine oleate to treat achalasia [75, 76] . Moreto et al performed injections ever 2-4 weeks until dysphagia resolved in 103 patients over the last 20 years. Th e primary outcome was dysphagia relief. Secondary outcomes were LES pressure, esophagogram, gastroesophageal refl ux, and endoscopic ultrasonography. Th ey reported a 90% of cumulative expectancy of being free of recurrence at 50 months [76] . Th ere is skepticism about this procedure because the fi brotic stricture might make more traditional therapies diffi cult to perform [16] .
Future therapies
All the present approaches for the treatment of achalasia are targeting the disruption of the esophagus rather than trying to correct the underlying abnormality and restore the motility function. In view of the fact that the enteric neurons innervating the esophagus and the LES could disappear due to an autoimmune mechanism, theoretically immunosuppressive therapy could be considered to prevent disease progression [77] . However, at the time of diagnosis, the number of neurons is already decreased, leading to signifi cant dysfunction and symptoms. Another experimental study in mice suggested that transplantation of neuronal stem cells might be a future therapeutic option [78] . Th e neurospheres, as they called the neural stem cells, can be isolated and cultured from mucosal biopsies as proven by Metzger et al. Th ey generated neurosphere-like bodies capable of proliferating and generating multiple neuronal subtypes; when transplanted, they colonized cultured aganglionic human hindgut to generate ganglia-like structures and enteric neurons and glia [79] . Unfortunately, aft er in vivo transplantation into the mice pylorus these neurosphere-like bodies failed to adopt a neuronal phenotype. Similar fi ndings were reported from other groups. Clearly, more research is required to develop optimized therapies and techniques of stem cell therapy to restore the functional anatomy of the LES.
Concluding remarks
Th e recent emergence of the HRM as a diagnostic tool has helped identify three subtypes of achalasia that show diff erent responsiveness to endoscopic or surgical therapies. Th is subclassifi cation has facilitated choosing the appropriate treatment for each diff erent patient, thereby increasing overall treatment effi cacy. In our opinion, high-risk older patients and those with severe comorbidities should undergo Botox, while all the other patients may be considered as low risk and off ered surgical or endoscopic treatment (Fig. 2) . Th e choice between PD or surgery may depend on local expertise.
Th e role of POEM as a valuable substitute of the traditional therapeutic options will be defi ned in the immediate future aft er randomized prospective comparison trials and longterm follow-up studies are published. Pharmacological therapy could be administered to patients waiting for an endoscopic or surgical treatment and to those with high surgical risk whenever the approach with Botox is not possible or has failed. While current treatment of achalasia still focuses on mechanical disruption of the LES, future therapies are anticipated aiming at restoring its function. 
